Table 3.
Grade 3-4 adverse events in patients with ER-positive metastatic breast cancer
| Adverse event | Palbociclib plus AI (n = 84) | Palbociclib plus fulvestrant (n = 88) |
|---|---|---|
| Leukopenia | ||
| Grade 3 | 6.0% | 6.8% |
| Neutropenia | ||
| Grade 3 | 34.5% | 36.4% |
| Grade 4 | 2.4% | 0% |
| Anemia | ||
| Grade 3 | 2.4% | 0% |
| Thrombocytopenia | ||
| Grade 3 | 1.2% | 2.3% |
| Nausea | ||
| Grade 3 | 1.2% | 0% |
| Pneumopathy | ||
| Grade 3 | 3.6% | 0% |
| Pain | ||
| Grade 3 | 1.2% | 4.5% |
| Other | ||
| Grade 3 | 6.0% | 0% |
| Grade 4 | 0% | 1.1% |